nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—Niacin—atherosclerosis	0.336	0.556	CbGbCtD
Amphetamine—CYP2D6—Niacin—atherosclerosis	0.0804	0.133	CbGbCtD
Amphetamine—CYP2D6—Simvastatin—atherosclerosis	0.0636	0.105	CbGbCtD
Amphetamine—CYP2D6—Pravastatin—atherosclerosis	0.0622	0.103	CbGbCtD
Amphetamine—CYP2D6—Lovastatin—atherosclerosis	0.0622	0.103	CbGbCtD
Amphetamine—Accidental injury—Rosuvastatin—atherosclerosis	0.00476	0.0194	CcSEcCtD
Amphetamine—Accidental injury—Lovastatin—atherosclerosis	0.00404	0.0165	CcSEcCtD
Amphetamine—Viral infection—Ezetimibe—atherosclerosis	0.00388	0.0158	CcSEcCtD
Amphetamine—Viral infection—Pravastatin—atherosclerosis	0.00334	0.0136	CcSEcCtD
Amphetamine—Injury—Rosuvastatin—atherosclerosis	0.00333	0.0136	CcSEcCtD
Amphetamine—Aspartame—TRPV1—atherosclerosis	0.00328	0.499	CrCbGaD
Amphetamine—Muscle twitching—Niacin—atherosclerosis	0.00312	0.0127	CcSEcCtD
Amphetamine—Injury—Lovastatin—atherosclerosis	0.00282	0.0115	CcSEcCtD
Amphetamine—Injury—Pravastatin—atherosclerosis	0.00239	0.00973	CcSEcCtD
Amphetamine—Depression—Rosuvastatin—atherosclerosis	0.00235	0.00959	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.00234	0.00952	CcSEcCtD
Amphetamine—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00229	0.00934	CcSEcCtD
Amphetamine—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00221	0.00901	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00218	0.00891	CcSEcCtD
Amphetamine—Affect lability—Pravastatin—atherosclerosis	0.00216	0.0088	CcSEcCtD
Amphetamine—Mood swings—Pravastatin—atherosclerosis	0.00208	0.00847	CcSEcCtD
Amphetamine—Erectile dysfunction—Lovastatin—atherosclerosis	0.00206	0.00842	CcSEcCtD
Amphetamine—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00205	0.00834	CcSEcCtD
Amphetamine—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00202	0.00825	CcSEcCtD
Amphetamine—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.00201	0.00818	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.00198	0.00808	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.00197	0.00805	CcSEcCtD
Amphetamine—Urinary tract infection—Lovastatin—atherosclerosis	0.00194	0.00792	CcSEcCtD
Amphetamine—Erectile dysfunction—Simvastatin—atherosclerosis	0.00193	0.00787	CcSEcCtD
Amphetamine—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00191	0.0078	CcSEcCtD
Amphetamine—Depression—Simvastatin—atherosclerosis	0.00186	0.0076	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.00185	0.00756	CcSEcCtD
Amphetamine—Erectile dysfunction—Niacin—atherosclerosis	0.00177	0.00723	CcSEcCtD
Amphetamine—Erectile dysfunction—Pravastatin—atherosclerosis	0.00175	0.00712	CcSEcCtD
Amphetamine—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00173	0.00705	CcSEcCtD
Amphetamine—Weight decreased—Pravastatin—atherosclerosis	0.00171	0.00699	CcSEcCtD
Amphetamine—Erythema multiforme—Lovastatin—atherosclerosis	0.0017	0.00692	CcSEcCtD
Amphetamine—Tolazoline—HRH1—atherosclerosis	0.00169	0.257	CrCbGaD
Amphetamine—Depression—Pravastatin—atherosclerosis	0.00169	0.00687	CcSEcCtD
Amphetamine—Angioedema—Rosuvastatin—atherosclerosis	0.00168	0.00686	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.00168	0.00683	CcSEcCtD
Amphetamine—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00167	0.00679	CcSEcCtD
Amphetamine—Erythema multiforme—Ezetimibe—atherosclerosis	0.00166	0.00678	CcSEcCtD
Amphetamine—Myocardial infarction—Pravastatin—atherosclerosis	0.00166	0.00675	CcSEcCtD
Amphetamine—Sweating—Niacin—atherosclerosis	0.00165	0.00671	CcSEcCtD
Amphetamine—Urinary tract infection—Pravastatin—atherosclerosis	0.00164	0.0067	CcSEcCtD
Amphetamine—Erythema multiforme—Simvastatin—atherosclerosis	0.00159	0.00647	CcSEcCtD
Amphetamine—Infection—Rosuvastatin—atherosclerosis	0.00149	0.00609	CcSEcCtD
Amphetamine—Tremor—Lovastatin—atherosclerosis	0.00146	0.00597	CcSEcCtD
Amphetamine—Erythema multiforme—Pravastatin—atherosclerosis	0.00143	0.00585	CcSEcCtD
Amphetamine—Angioedema—Lovastatin—atherosclerosis	0.00143	0.00582	CcSEcCtD
Amphetamine—Angioedema—Ezetimibe—atherosclerosis	0.0014	0.00571	CcSEcCtD
Amphetamine—Tremor—Simvastatin—atherosclerosis	0.00137	0.00558	CcSEcCtD
Amphetamine—Insomnia—Rosuvastatin—atherosclerosis	0.00136	0.00555	CcSEcCtD
Amphetamine—Palpitations—Ezetimibe—atherosclerosis	0.00135	0.00552	CcSEcCtD
Amphetamine—Angioedema—Simvastatin—atherosclerosis	0.00133	0.00544	CcSEcCtD
Amphetamine—Chest pain—Lovastatin—atherosclerosis	0.00133	0.00542	CcSEcCtD
Amphetamine—Anxiety—Lovastatin—atherosclerosis	0.00132	0.0054	CcSEcCtD
Amphetamine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00132	0.0054	CcSEcCtD
Amphetamine—Hypertension—Ezetimibe—atherosclerosis	0.00132	0.00539	CcSEcCtD
Amphetamine—Tension—Niacin—atherosclerosis	0.00132	0.00537	CcSEcCtD
Amphetamine—Chest pain—Ezetimibe—atherosclerosis	0.0013	0.00532	CcSEcCtD
Amphetamine—Nervousness—Niacin—atherosclerosis	0.0013	0.00531	CcSEcCtD
Amphetamine—Dry mouth—Lovastatin—atherosclerosis	0.0013	0.0053	CcSEcCtD
Amphetamine—Tension—Pravastatin—atherosclerosis	0.0013	0.00528	CcSEcCtD
Amphetamine—Constipation—Rosuvastatin—atherosclerosis	0.00129	0.00524	CcSEcCtD
Amphetamine—Nervousness—Pravastatin—atherosclerosis	0.00128	0.00523	CcSEcCtD
Amphetamine—Dry mouth—Ezetimibe—atherosclerosis	0.00128	0.0052	CcSEcCtD
Amphetamine—Anaphylactic shock—Lovastatin—atherosclerosis	0.00127	0.0052	CcSEcCtD
Amphetamine—Infection—Lovastatin—atherosclerosis	0.00127	0.00516	CcSEcCtD
Amphetamine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00125	0.0051	CcSEcCtD
Amphetamine—Chest pain—Simvastatin—atherosclerosis	0.00124	0.00507	CcSEcCtD
Amphetamine—Infection—Ezetimibe—atherosclerosis	0.00124	0.00506	CcSEcCtD
Amphetamine—Anxiety—Simvastatin—atherosclerosis	0.00124	0.00505	CcSEcCtD
Amphetamine—Tremor—Pravastatin—atherosclerosis	0.00124	0.00504	CcSEcCtD
Amphetamine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00123	0.00501	CcSEcCtD
Amphetamine—Angioedema—Niacin—atherosclerosis	0.00123	0.005	CcSEcCtD
Amphetamine—Anorexia—Lovastatin—atherosclerosis	0.00121	0.00495	CcSEcCtD
Amphetamine—Angioedema—Pravastatin—atherosclerosis	0.00121	0.00492	CcSEcCtD
Amphetamine—Urticaria—Rosuvastatin—atherosclerosis	0.00119	0.00487	CcSEcCtD
Amphetamine—Anaphylactic shock—Simvastatin—atherosclerosis	0.00119	0.00486	CcSEcCtD
Amphetamine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00119	0.00485	CcSEcCtD
Amphetamine—Palpitations—Niacin—atherosclerosis	0.00119	0.00483	CcSEcCtD
Amphetamine—Infection—Simvastatin—atherosclerosis	0.00118	0.00483	CcSEcCtD
Amphetamine—Insomnia—Lovastatin—atherosclerosis	0.00115	0.0047	CcSEcCtD
Amphetamine—Hypertension—Pravastatin—atherosclerosis	0.00114	0.00465	CcSEcCtD
Amphetamine—Anorexia—Simvastatin—atherosclerosis	0.00114	0.00463	CcSEcCtD
Amphetamine—Dyspnoea—Lovastatin—atherosclerosis	0.00114	0.00463	CcSEcCtD
Amphetamine—Insomnia—Ezetimibe—atherosclerosis	0.00113	0.00461	CcSEcCtD
Amphetamine—Chest pain—Pravastatin—atherosclerosis	0.00112	0.00458	CcSEcCtD
Amphetamine—Dyspepsia—Lovastatin—atherosclerosis	0.00112	0.00457	CcSEcCtD
Amphetamine—Anxiety—Pravastatin—atherosclerosis	0.00112	0.00457	CcSEcCtD
Amphetamine—Dry mouth—Niacin—atherosclerosis	0.00112	0.00455	CcSEcCtD
Amphetamine—Dyspnoea—Ezetimibe—atherosclerosis	0.00111	0.00454	CcSEcCtD
Amphetamine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00111	0.00452	CcSEcCtD
Amphetamine—Decreased appetite—Lovastatin—atherosclerosis	0.00111	0.00452	CcSEcCtD
Amphetamine—Dyspepsia—Ezetimibe—atherosclerosis	0.0011	0.00449	CcSEcCtD
Amphetamine—Fatigue—Lovastatin—atherosclerosis	0.0011	0.00448	CcSEcCtD
Amphetamine—Anaphylactic shock—Niacin—atherosclerosis	0.00109	0.00446	CcSEcCtD
Amphetamine—Constipation—Lovastatin—atherosclerosis	0.00109	0.00444	CcSEcCtD
Amphetamine—Decreased appetite—Ezetimibe—atherosclerosis	0.00109	0.00443	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00108	0.0044	CcSEcCtD
Amphetamine—Asthenia—Rosuvastatin—atherosclerosis	0.00108	0.0044	CcSEcCtD
Amphetamine—Insomnia—Simvastatin—atherosclerosis	0.00108	0.0044	CcSEcCtD
Amphetamine—Anaphylactic shock—Pravastatin—atherosclerosis	0.00108	0.00439	CcSEcCtD
Amphetamine—Fatigue—Ezetimibe—atherosclerosis	0.00108	0.00439	CcSEcCtD
Amphetamine—Infection—Pravastatin—atherosclerosis	0.00107	0.00437	CcSEcCtD
Amphetamine—Constipation—Ezetimibe—atherosclerosis	0.00107	0.00436	CcSEcCtD
Amphetamine—Tachycardia—Niacin—atherosclerosis	0.00107	0.00436	CcSEcCtD
Amphetamine—Dyspnoea—Simvastatin—atherosclerosis	0.00106	0.00433	CcSEcCtD
Amphetamine—Hyperhidrosis—Niacin—atherosclerosis	0.00106	0.00431	CcSEcCtD
Amphetamine—Dyspepsia—Simvastatin—atherosclerosis	0.00105	0.00428	CcSEcCtD
Amphetamine—Anorexia—Niacin—atherosclerosis	0.00104	0.00425	CcSEcCtD
Amphetamine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00104	0.00425	CcSEcCtD
Amphetamine—Hyperhidrosis—Pravastatin—atherosclerosis	0.00104	0.00425	CcSEcCtD
Amphetamine—Decreased appetite—Simvastatin—atherosclerosis	0.00104	0.00423	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00103	0.0042	CcSEcCtD
Amphetamine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00103	0.0042	CcSEcCtD
Amphetamine—Fatigue—Simvastatin—atherosclerosis	0.00103	0.00419	CcSEcCtD
Amphetamine—Anorexia—Pravastatin—atherosclerosis	0.00103	0.00419	CcSEcCtD
Amphetamine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00102	0.00417	CcSEcCtD
Amphetamine—Constipation—Simvastatin—atherosclerosis	0.00102	0.00416	CcSEcCtD
Amphetamine—Urticaria—Lovastatin—atherosclerosis	0.00101	0.00413	CcSEcCtD
Amphetamine—Abdominal pain—Lovastatin—atherosclerosis	0.00101	0.00411	CcSEcCtD
Amphetamine—Body temperature increased—Lovastatin—atherosclerosis	0.00101	0.00411	CcSEcCtD
Amphetamine—Dizziness—Rosuvastatin—atherosclerosis	0.000995	0.00405	CcSEcCtD
Amphetamine—Urticaria—Ezetimibe—atherosclerosis	0.000993	0.00405	CcSEcCtD
Amphetamine—Insomnia—Niacin—atherosclerosis	0.00099	0.00404	CcSEcCtD
Amphetamine—Abdominal pain—Ezetimibe—atherosclerosis	0.000988	0.00403	CcSEcCtD
Amphetamine—Body temperature increased—Ezetimibe—atherosclerosis	0.000988	0.00403	CcSEcCtD
Amphetamine—Dyspnoea—Niacin—atherosclerosis	0.000976	0.00398	CcSEcCtD
Amphetamine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000975	0.00397	CcSEcCtD
Amphetamine—Insomnia—Pravastatin—atherosclerosis	0.000975	0.00397	CcSEcCtD
Amphetamine—Somnolence—Niacin—atherosclerosis	0.000973	0.00397	CcSEcCtD
Amphetamine—Dyspepsia—Niacin—atherosclerosis	0.000964	0.00393	CcSEcCtD
Amphetamine—Dyspnoea—Pravastatin—atherosclerosis	0.000961	0.00392	CcSEcCtD
Amphetamine—Decreased appetite—Niacin—atherosclerosis	0.000952	0.00388	CcSEcCtD
Amphetamine—Dyspepsia—Pravastatin—atherosclerosis	0.000949	0.00387	CcSEcCtD
Amphetamine—Rash—Rosuvastatin—atherosclerosis	0.000948	0.00387	CcSEcCtD
Amphetamine—Dermatitis—Rosuvastatin—atherosclerosis	0.000947	0.00386	CcSEcCtD
Amphetamine—Urticaria—Simvastatin—atherosclerosis	0.000947	0.00386	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000945	0.00385	CcSEcCtD
Amphetamine—Abdominal pain—Simvastatin—atherosclerosis	0.000942	0.00384	CcSEcCtD
Amphetamine—Body temperature increased—Simvastatin—atherosclerosis	0.000942	0.00384	CcSEcCtD
Amphetamine—Headache—Rosuvastatin—atherosclerosis	0.000942	0.00384	CcSEcCtD
Amphetamine—Hypersensitivity—Lovastatin—atherosclerosis	0.000939	0.00383	CcSEcCtD
Amphetamine—Decreased appetite—Pravastatin—atherosclerosis	0.000937	0.00382	CcSEcCtD
Amphetamine—Fatigue—Pravastatin—atherosclerosis	0.000929	0.00379	CcSEcCtD
Amphetamine—Constipation—Pravastatin—atherosclerosis	0.000922	0.00376	CcSEcCtD
Amphetamine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000921	0.00376	CcSEcCtD
Amphetamine—Asthenia—Lovastatin—atherosclerosis	0.000914	0.00373	CcSEcCtD
Amphetamine—Asthenia—Ezetimibe—atherosclerosis	0.000897	0.00366	CcSEcCtD
Amphetamine—Gastrointestinal pain—Niacin—atherosclerosis	0.000895	0.00365	CcSEcCtD
Amphetamine—Nausea—Rosuvastatin—atherosclerosis	0.000893	0.00364	CcSEcCtD
Amphetamine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000881	0.00359	CcSEcCtD
Amphetamine—Hypersensitivity—Simvastatin—atherosclerosis	0.000878	0.00358	CcSEcCtD
Amphetamine—Diarrhoea—Lovastatin—atherosclerosis	0.000872	0.00356	CcSEcCtD
Amphetamine—Urticaria—Niacin—atherosclerosis	0.00087	0.00355	CcSEcCtD
Amphetamine—Body temperature increased—Niacin—atherosclerosis	0.000865	0.00353	CcSEcCtD
Amphetamine—Abdominal pain—Niacin—atherosclerosis	0.000865	0.00353	CcSEcCtD
Amphetamine—Urticaria—Pravastatin—atherosclerosis	0.000856	0.00349	CcSEcCtD
Amphetamine—Asthenia—Simvastatin—atherosclerosis	0.000855	0.00349	CcSEcCtD
Amphetamine—Diarrhoea—Ezetimibe—atherosclerosis	0.000855	0.00349	CcSEcCtD
Amphetamine—Abdominal pain—Pravastatin—atherosclerosis	0.000852	0.00347	CcSEcCtD
Amphetamine—Body temperature increased—Pravastatin—atherosclerosis	0.000852	0.00347	CcSEcCtD
Amphetamine—Dizziness—Lovastatin—atherosclerosis	0.000843	0.00344	CcSEcCtD
Amphetamine—Dizziness—Ezetimibe—atherosclerosis	0.000827	0.00337	CcSEcCtD
Amphetamine—Diarrhoea—Simvastatin—atherosclerosis	0.000816	0.00333	CcSEcCtD
Amphetamine—Vomiting—Lovastatin—atherosclerosis	0.00081	0.0033	CcSEcCtD
Amphetamine—Hypersensitivity—Niacin—atherosclerosis	0.000806	0.00329	CcSEcCtD
Amphetamine—Rash—Lovastatin—atherosclerosis	0.000804	0.00328	CcSEcCtD
Amphetamine—Dermatitis—Lovastatin—atherosclerosis	0.000803	0.00327	CcSEcCtD
Amphetamine—Headache—Lovastatin—atherosclerosis	0.000798	0.00326	CcSEcCtD
Amphetamine—Vomiting—Ezetimibe—atherosclerosis	0.000795	0.00324	CcSEcCtD
Amphetamine—Hypersensitivity—Pravastatin—atherosclerosis	0.000794	0.00324	CcSEcCtD
Amphetamine—Dizziness—Simvastatin—atherosclerosis	0.000788	0.00321	CcSEcCtD
Amphetamine—Rash—Ezetimibe—atherosclerosis	0.000788	0.00321	CcSEcCtD
Amphetamine—Dermatitis—Ezetimibe—atherosclerosis	0.000787	0.00321	CcSEcCtD
Amphetamine—Asthenia—Niacin—atherosclerosis	0.000785	0.0032	CcSEcCtD
Amphetamine—Headache—Ezetimibe—atherosclerosis	0.000783	0.00319	CcSEcCtD
Amphetamine—Asthenia—Pravastatin—atherosclerosis	0.000773	0.00315	CcSEcCtD
Amphetamine—Vomiting—Simvastatin—atherosclerosis	0.000758	0.00309	CcSEcCtD
Amphetamine—Nausea—Lovastatin—atherosclerosis	0.000757	0.00309	CcSEcCtD
Amphetamine—Rash—Simvastatin—atherosclerosis	0.000752	0.00306	CcSEcCtD
Amphetamine—Dermatitis—Simvastatin—atherosclerosis	0.000751	0.00306	CcSEcCtD
Amphetamine—Diarrhoea—Niacin—atherosclerosis	0.000749	0.00305	CcSEcCtD
Amphetamine—Headache—Simvastatin—atherosclerosis	0.000747	0.00304	CcSEcCtD
Amphetamine—Nausea—Ezetimibe—atherosclerosis	0.000743	0.00303	CcSEcCtD
Amphetamine—Diarrhoea—Pravastatin—atherosclerosis	0.000737	0.00301	CcSEcCtD
Amphetamine—Dizziness—Niacin—atherosclerosis	0.000724	0.00295	CcSEcCtD
Amphetamine—Dizziness—Pravastatin—atherosclerosis	0.000713	0.00291	CcSEcCtD
Amphetamine—Nausea—Simvastatin—atherosclerosis	0.000708	0.00289	CcSEcCtD
Amphetamine—Vomiting—Niacin—atherosclerosis	0.000696	0.00284	CcSEcCtD
Amphetamine—Rash—Niacin—atherosclerosis	0.00069	0.00281	CcSEcCtD
Amphetamine—Dermatitis—Niacin—atherosclerosis	0.00069	0.00281	CcSEcCtD
Amphetamine—Headache—Niacin—atherosclerosis	0.000686	0.0028	CcSEcCtD
Amphetamine—Vomiting—Pravastatin—atherosclerosis	0.000685	0.00279	CcSEcCtD
Amphetamine—Pseudoephedrine—TNF—atherosclerosis	0.000682	0.104	CrCbGaD
Amphetamine—Rash—Pravastatin—atherosclerosis	0.00068	0.00277	CcSEcCtD
Amphetamine—Dermatitis—Pravastatin—atherosclerosis	0.000679	0.00277	CcSEcCtD
Amphetamine—Headache—Pravastatin—atherosclerosis	0.000675	0.00275	CcSEcCtD
Amphetamine—Nateglinide—PPARG—atherosclerosis	0.00067	0.102	CrCbGaD
Amphetamine—Nausea—Niacin—atherosclerosis	0.00065	0.00265	CcSEcCtD
Amphetamine—Nausea—Pravastatin—atherosclerosis	0.00064	0.00261	CcSEcCtD
Amphetamine—Nateglinide—ALB—atherosclerosis	0.000252	0.0383	CrCbGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—atherosclerosis	5.79e-05	0.000403	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOA4—atherosclerosis	5.73e-05	0.000399	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CNR2—atherosclerosis	5.7e-05	0.000398	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—MAPK3—atherosclerosis	5.69e-05	0.000397	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HMGCR—atherosclerosis	5.66e-05	0.000395	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—INS—atherosclerosis	5.63e-05	0.000392	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP7A1—atherosclerosis	5.63e-05	0.000392	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	5.59e-05	0.00039	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—atherosclerosis	5.56e-05	0.000388	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ALB—atherosclerosis	5.55e-05	0.000387	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—MAPK8—atherosclerosis	5.54e-05	0.000386	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL2—atherosclerosis	5.54e-05	0.000386	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ALB—atherosclerosis	5.53e-05	0.000386	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—APOA1—atherosclerosis	5.45e-05	0.00038	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1—atherosclerosis	5.44e-05	0.000379	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LDLRAP1—atherosclerosis	5.4e-05	0.000376	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP27A1—atherosclerosis	5.2e-05	0.000362	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—AGT—atherosclerosis	5.17e-05	0.000361	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SERPINE1—atherosclerosis	5.17e-05	0.00036	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—atherosclerosis	5.15e-05	0.000359	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HMOX1—atherosclerosis	5.12e-05	0.000357	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLTP—atherosclerosis	5.08e-05	0.000354	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCA1—atherosclerosis	5.05e-05	0.000352	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NOS3—atherosclerosis	4.93e-05	0.000344	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLA2G2A—atherosclerosis	4.93e-05	0.000344	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALOX15—atherosclerosis	4.93e-05	0.000344	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOA2—atherosclerosis	4.93e-05	0.000344	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALOX5AP—atherosclerosis	4.93e-05	0.000344	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL3—atherosclerosis	4.9e-05	0.000342	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOB—atherosclerosis	4.9e-05	0.000342	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCR2—atherosclerosis	4.88e-05	0.000341	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—EDNRA—atherosclerosis	4.88e-05	0.000341	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCG5—atherosclerosis	4.87e-05	0.000339	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—APOA1—atherosclerosis	4.83e-05	0.000337	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—F2—atherosclerosis	4.78e-05	0.000333	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTM1—atherosclerosis	4.77e-05	0.000332	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GHRL—atherosclerosis	4.76e-05	0.000332	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LPA—atherosclerosis	4.7e-05	0.000328	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—LPL—atherosclerosis	4.68e-05	0.000326	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOA4—atherosclerosis	4.6e-05	0.000321	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GPX1—atherosclerosis	4.57e-05	0.000318	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—BGN—atherosclerosis	4.55e-05	0.000317	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOA5—atherosclerosis	4.51e-05	0.000314	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CD36—atherosclerosis	4.45e-05	0.00031	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCR2—atherosclerosis	4.44e-05	0.000309	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDNRA—atherosclerosis	4.44e-05	0.000309	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	4.42e-05	0.000308	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCG8—atherosclerosis	4.4e-05	0.000307	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LTA4H—atherosclerosis	4.4e-05	0.000307	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—atherosclerosis	4.38e-05	0.000305	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLA2G1B—atherosclerosis	4.34e-05	0.000303	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HMOX1—atherosclerosis	4.33e-05	0.000302	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GHRL—atherosclerosis	4.32e-05	0.000301	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—atherosclerosis	4.32e-05	0.000301	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL2—atherosclerosis	4.26e-05	0.000297	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL4—atherosclerosis	4.24e-05	0.000296	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—atherosclerosis	4.23e-05	0.000295	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MTHFR—atherosclerosis	4.21e-05	0.000294	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALOX5—atherosclerosis	4.19e-05	0.000292	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—KNG1—atherosclerosis	4.18e-05	0.000291	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—atherosclerosis	4.16e-05	0.00029	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AGTR1—atherosclerosis	4.15e-05	0.00029	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOB—atherosclerosis	4.15e-05	0.000289	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARA—atherosclerosis	4.13e-05	0.000288	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTM1—atherosclerosis	4.03e-05	0.000281	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AGT—atherosclerosis	4e-05	0.000279	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOA2—atherosclerosis	3.96e-05	0.000276	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—LPL—atherosclerosis	3.96e-05	0.000276	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—atherosclerosis	3.96e-05	0.000276	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOE—atherosclerosis	3.92e-05	0.000273	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NFKB1—atherosclerosis	3.92e-05	0.000273	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CAV1—atherosclerosis	3.89e-05	0.000271	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOA1—atherosclerosis	3.88e-05	0.00027	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GPX1—atherosclerosis	3.86e-05	0.000269	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK8—atherosclerosis	3.85e-05	0.000268	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—atherosclerosis	3.84e-05	0.000268	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—atherosclerosis	3.83e-05	0.000267	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KNG1—atherosclerosis	3.79e-05	0.000264	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—UTS2—atherosclerosis	3.78e-05	0.000264	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AGTR1—atherosclerosis	3.77e-05	0.000263	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CD36—atherosclerosis	3.76e-05	0.000262	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NAMPT—atherosclerosis	3.76e-05	0.000262	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LIPC—atherosclerosis	3.74e-05	0.00026	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOC3—atherosclerosis	3.71e-05	0.000259	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LDLR—atherosclerosis	3.69e-05	0.000257	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CX3CR1—atherosclerosis	3.62e-05	0.000253	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASR—atherosclerosis	3.62e-05	0.000253	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CETP—atherosclerosis	3.6e-05	0.000251	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—atherosclerosis	3.57e-05	0.000249	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—atherosclerosis	3.56e-05	0.000248	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CX3CL1—atherosclerosis	3.55e-05	0.000248	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CG—atherosclerosis	3.54e-05	0.000247	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—atherosclerosis	3.54e-05	0.000247	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—EDN1—atherosclerosis	3.52e-05	0.000245	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—atherosclerosis	3.52e-05	0.000245	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARA—atherosclerosis	3.5e-05	0.000244	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCL5—atherosclerosis	3.49e-05	0.000244	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCG1—atherosclerosis	3.48e-05	0.000243	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SCARB1—atherosclerosis	3.45e-05	0.000241	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARG—atherosclerosis	3.42e-05	0.000238	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AGT—atherosclerosis	3.39e-05	0.000236	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CNR2—atherosclerosis	3.37e-05	0.000235	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—atherosclerosis	3.37e-05	0.000235	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK3—atherosclerosis	3.36e-05	0.000234	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MMP3—atherosclerosis	3.36e-05	0.000234	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—INS—atherosclerosis	3.35e-05	0.000234	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PRKCG—atherosclerosis	3.32e-05	0.000232	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOE—atherosclerosis	3.32e-05	0.000231	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CAV1—atherosclerosis	3.29e-05	0.000229	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOA1—atherosclerosis	3.28e-05	0.000229	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FABP4—atherosclerosis	3.27e-05	0.000228	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LCAT—atherosclerosis	3.27e-05	0.000228	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TGFB1—atherosclerosis	3.26e-05	0.000227	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HMGCR—atherosclerosis	3.26e-05	0.000227	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOA4—atherosclerosis	3.21e-05	0.000224	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDN1—atherosclerosis	3.2e-05	0.000223	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL5—atherosclerosis	3.17e-05	0.000221	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP7A1—atherosclerosis	3.15e-05	0.00022	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALB—atherosclerosis	3.07e-05	0.000214	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PRKCG—atherosclerosis	3.02e-05	0.00021	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VWF—atherosclerosis	3e-05	0.000209	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CG—atherosclerosis	3e-05	0.000209	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOC3—atherosclerosis	2.98e-05	0.000208	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LDLR—atherosclerosis	2.97e-05	0.000207	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NOS3—atherosclerosis	2.94e-05	0.000205	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AGT—atherosclerosis	2.92e-05	0.000204	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP27A1—atherosclerosis	2.92e-05	0.000203	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCA1—atherosclerosis	2.91e-05	0.000203	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL3—atherosclerosis	2.9e-05	0.000202	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARG—atherosclerosis	2.89e-05	0.000202	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—INS—atherosclerosis	2.84e-05	0.000198	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NCF1—atherosclerosis	2.77e-05	0.000193	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	2.76e-05	0.000193	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOA2—atherosclerosis	2.76e-05	0.000193	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALOX15—atherosclerosis	2.76e-05	0.000193	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	2.76e-05	0.000193	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCG5—atherosclerosis	2.73e-05	0.00019	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—F2—atherosclerosis	2.7e-05	0.000188	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—atherosclerosis	2.69e-05	0.000187	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AGT—atherosclerosis	2.65e-05	0.000185	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LPA—atherosclerosis	2.64e-05	0.000184	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR2—atherosclerosis	2.62e-05	0.000183	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDNRA—atherosclerosis	2.62e-05	0.000183	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CYBA—atherosclerosis	2.61e-05	0.000182	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALB—atherosclerosis	2.6e-05	0.000181	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CG—atherosclerosis	2.58e-05	0.00018	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—BGN—atherosclerosis	2.55e-05	0.000178	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GHRL—atherosclerosis	2.55e-05	0.000178	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PARP1—atherosclerosis	2.55e-05	0.000178	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PLAT—atherosclerosis	2.55e-05	0.000178	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOA5—atherosclerosis	2.53e-05	0.000176	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HMOX1—atherosclerosis	2.49e-05	0.000174	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NOS3—atherosclerosis	2.49e-05	0.000173	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—atherosclerosis	2.46e-05	0.000171	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—F2—atherosclerosis	2.45e-05	0.000171	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	2.43e-05	0.00017	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOB—atherosclerosis	2.39e-05	0.000166	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALOX5—atherosclerosis	2.35e-05	0.000164	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CG—atherosclerosis	2.35e-05	0.000164	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—atherosclerosis	2.32e-05	0.000162	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LPL—atherosclerosis	2.28e-05	0.000159	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—atherosclerosis	2.27e-05	0.000159	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—atherosclerosis	2.27e-05	0.000158	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KNG1—atherosclerosis	2.24e-05	0.000156	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGTR1—atherosclerosis	2.23e-05	0.000155	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GPX1—atherosclerosis	2.22e-05	0.000155	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL2—atherosclerosis	2.19e-05	0.000152	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PLG—atherosclerosis	2.17e-05	0.000151	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CD36—atherosclerosis	2.17e-05	0.000151	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NAMPT—atherosclerosis	2.11e-05	0.000147	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LIPC—atherosclerosis	2.1e-05	0.000146	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOC3—atherosclerosis	2.08e-05	0.000145	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LDLR—atherosclerosis	2.07e-05	0.000144	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SOCS3—atherosclerosis	2.06e-05	0.000143	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—atherosclerosis	2.05e-05	0.000143	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CETP—atherosclerosis	2.02e-05	0.000141	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARA—atherosclerosis	2.01e-05	0.00014	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP3—atherosclerosis	1.99e-05	0.000138	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF2—atherosclerosis	1.98e-05	0.000138	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AGT—atherosclerosis	1.95e-05	0.000136	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.94e-05	0.000135	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOB—atherosclerosis	1.92e-05	0.000134	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOE—atherosclerosis	1.91e-05	0.000133	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	1.9e-05	0.000133	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CAV1—atherosclerosis	1.89e-05	0.000132	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOA1—atherosclerosis	1.89e-05	0.000132	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDN1—atherosclerosis	1.89e-05	0.000132	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL5—atherosclerosis	1.87e-05	0.000131	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LPL—atherosclerosis	1.83e-05	0.000128	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.83e-05	0.000127	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKCG—atherosclerosis	1.78e-05	0.000124	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SPP1—atherosclerosis	1.74e-05	0.000121	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	1.73e-05	0.00012	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CG—atherosclerosis	1.72e-05	0.00012	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARG—atherosclerosis	1.66e-05	0.000116	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—INS—atherosclerosis	1.63e-05	0.000114	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.63e-05	0.000114	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDGFB—atherosclerosis	1.61e-05	0.000112	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGT—atherosclerosis	1.57e-05	0.000109	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LEP—atherosclerosis	1.54e-05	0.000107	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOE—atherosclerosis	1.54e-05	0.000107	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CAV1—atherosclerosis	1.52e-05	0.000106	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOA1—atherosclerosis	1.52e-05	0.000106	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALB—atherosclerosis	1.5e-05	0.000104	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ESR1—atherosclerosis	1.47e-05	0.000102	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—F2—atherosclerosis	1.45e-05	0.000101	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NOS3—atherosclerosis	1.43e-05	9.98e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.4e-05	9.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	1.39e-05	9.66e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—atherosclerosis	1.35e-05	9.42e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOB—atherosclerosis	1.34e-05	9.33e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	1.33e-05	9.26e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INS—atherosclerosis	1.31e-05	9.15e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—atherosclerosis	1.31e-05	9.13e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.3e-05	9.08e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL2—atherosclerosis	1.29e-05	9e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LPL—atherosclerosis	1.28e-05	8.91e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1—atherosclerosis	1.27e-05	8.85e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPX1—atherosclerosis	1.25e-05	8.69e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CD36—atherosclerosis	1.21e-05	8.47e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.21e-05	8.4e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.15e-05	8.02e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.15e-05	8.02e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—atherosclerosis	1.14e-05	7.97e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARA—atherosclerosis	1.13e-05	7.87e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AGT—atherosclerosis	1.09e-05	7.62e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOE—atherosclerosis	1.07e-05	7.47e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CAV1—atherosclerosis	1.06e-05	7.4e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOA1—atherosclerosis	1.06e-05	7.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.02e-05	7.12e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	9.86e-06	6.87e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—atherosclerosis	9.71e-06	6.77e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	9.67e-06	6.74e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARG—atherosclerosis	9.33e-06	6.51e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—atherosclerosis	9.23e-06	6.44e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—INS—atherosclerosis	9.16e-06	6.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	9.14e-06	6.37e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	8.98e-06	6.26e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	8.96e-06	6.24e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALB—atherosclerosis	8.39e-06	5.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	8.29e-06	5.78e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—atherosclerosis	8.21e-06	5.72e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NOS3—atherosclerosis	8.03e-06	5.6e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	7.84e-06	5.47e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	7.61e-06	5.3e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—atherosclerosis	7.34e-06	5.12e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—atherosclerosis	6.58e-06	4.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—atherosclerosis	5.73e-06	4e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—atherosclerosis	5.29e-06	3.69e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—atherosclerosis	3.69e-06	2.57e-05	CbGpPWpGaD
